Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
about
Gut dysfunction in Parkinson's diseaseImpact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease.Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureProblems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Advances in dopamine receptor agonists for the treatment of Parkinson's disease.The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's DiseaseMagnetic Resonance Imaging as a Noninvasive Method for Longitudinal Monitoring of Infusion Site Reactions Following Administration of a Novel Apomorphine Formulation.Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study.The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.Secretome of Undifferentiated Neural Progenitor Cells Induces Histological and Motor Improvements in a Rat Model of Parkinson's DiseaseSerotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
P2860
Q26739037-0C7D7F3E-1759-4D08-9F29-6E5D00713326Q33722420-FF265EF3-EA82-472D-9B5C-DAB379AC03FBQ33917283-8DB66ADE-5CDB-418F-8409-254C890CC502Q33917419-9D4AB59C-C498-44F5-92F7-5966A23C5729Q38811387-E943C7FA-3FCA-4456-969A-7197925CC394Q38937096-85AA2D2D-257F-4577-A593-5B670AFAFB59Q39099746-297632D5-867F-4A69-B063-D7BCEE19997DQ41849974-9FD41391-099F-4C38-9D2C-AFA37E304756Q47782272-86760CB3-8461-4AE5-8C87-5648FD4472E4Q47868277-8AB4BF21-F653-4088-9780-3CF34603D578Q48236134-6136EB65-22A6-4E6D-9887-E74232F50F27Q48330188-4C2D7215-3050-4DFC-B80B-DF3492E3FA8FQ52316533-517186C7-459C-462F-8433-FCF750FD93C4Q58708199-F4EE7B1A-6A37-40D7-849F-8E1CEB9E4889Q58733645-E9ABE0D9-7CD6-4B5E-8E96-1B0DE1CCDEDF
P2860
Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Expert Consensus Group report ...... ical practice recommendations.
@en
type
label
Expert Consensus Group report ...... ical practice recommendations.
@en
prefLabel
Expert Consensus Group report ...... ical practice recommendations.
@en
P2093
P50
P1476
Expert Consensus Group report ...... ical practice recommendations.
@en
P2093
Andres Ceballos-Baumann
Andrew Evans
Expert Consensus Group for Use of Apomorphine in Parkinson's Disease
Georg Ebersbach
Georgios Tagaris
John O'Sullivan
Juan Carlos Martínez Castrillo
Karoline Wenzel
Mary Baker
Pedro J García Ruiz
P304
P356
10.1016/J.PARKRELDIS.2015.06.012
P50
P577
2015-06-17T00:00:00Z